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The plasma membranes of human erythrocytes (E) 1 (1), polymorphonuclear leu- 
kocytes (PMN) (2, 3), monocytes (4), macrophages (2), B lymphocytes (2), mast cells 
(5), and visceral epithelial cells of the glomerulus (6) have receptors for C3b, the major 
cleavage fragment of C3, that mediate the attachment to these cells of complexes that 
bear this complement protein.  Studies of the function of the C3b receptor on these 
cells  have defined its  participation  in  phagocytic  (3,  7-12)  and  secretory reactions 
(13-15),  but  physiocochemical  characterization  of the  receptor  is  limited  to  the 
demonstration of its trypsin sensitivity (2, 4), which suggests that it is a protein. 
Recently, a  205,000-mol  wt  glycoprotein  (gp205)  with  inhibitory  activity in  the 
human alternative complement pathway was solubilized from human E membranes 
with  Nonidet  P-40  (NP-40)  and was purified  to homogeneity by use of chromato- 
graphic procedures that included reversible adsorption to Sepharose-C3 (16). Purified 
gp205 was shown to accelerate the decay of the properdin (P)-stabilized amplification 
C3 convertase (C3b,Bb,P) by displacing Bb from C3b, and to promote cleavage of 
the a-polypeptide chain  of C3b by C3b inactivator  (C3bINA).  As these inhibitory 
functions of gp205, and its capacity to bind to Sepharose-C3, indicated an affinity of 
this membrane-derived glycoprotein for C3b, its possible identity as the C3b receptor 
was examined. 
This  study  demonstrates  that  rabbit  antibody  to  gp205  inhibits  C3b  receptor 
function not only on human  E, but also on PMN, B lymphocytes, and  monocytes. 
Interaction of anti-gp205  with solubilized, radioiodinated  membrane proteins from 
each of these cells immunoprecipitates a single membrane protein with an apparent 
205,000 mol wt on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS- 
PAGE). Thus, the C3b receptor of these four cell types is gp205. 
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Materials  and  Methods 
Preparation and Assay of Rabbit Antibody to gp205,  gp205 was solubilized from membranes of 
human  E  by use of NP-40  (Shell Chemical Co., New York) and was purified by sequential 
cation-exchange chromatography, affinity chromatography on Sepharose-C3, gel filtration, and 
affinity chromatography on Sepharose- (Pharmacia Fine Chemicals, Div. of Pharmacia, Inc., 
Piscataway, N.J.) lentil lectin (Sigma Chemical Co., St. Louis, Mo.) (16).  Purified gp205 was 
homogeneous when analyzed by SDS-PAGE, with or without prior reduction of disulfides. A 
rabbit was  immunized with  75 #g of gp205  emulsified in Freund's complete adjuvant  and 
boosted 5 wk later by intramuscular injection of an additional 50 #g in incomplete Freund's 
adjuvant. Antiserum was obtained from the rabbit 2 wk after boosting, and the IgG fraction 
was  prepared  by precipitation in  50%  ammonium  sulfate and  chromatography  on  DE52- 
cellulose. The IgG was digested (17) with pepsin (Worthington Biochemical Corp., Freehold, 
N.J.) and the F(ab')2 fragments were isolated by gel filtration of the digest on Sephadex G-200 
(Pharmacia Fine Chemicals, Div. of Pharmacia, Inc.). Serum that had been obtained from the 
same rabbit before immunization was processed in an identical manner to prepare preimmun- 
ization IgG and F(ab')2. Both preimmunization F(ab')2 and anti-gp205 F(ab')2 demonstrated 
single protein bands having apparent  100,000  mol wt on SDS-PAGE. Anti-gp205 F(ab')2 was 
labeled to a specific activity of 100,000 cpm/#g with l~I (New England Nuclear, Boston, Mass.) 
by use of insoluble lactoperoxidase (Worthington Biochemical Corp.) (18). 
Neutralization by anti-gp205 IgG of the capacity of purified gp205 to accelerate decay of 
C3b,Bb,P was measured by hemolytic assay. Dilutions of preimmunization IgG or anti-gp205 
IgG were incubated for 60 rain at 4°C with 2 ng gp205 in 0.1 ml of veronal-buffered saline that 
contained 0.1% gelatin and 20 mM EDTA.  1 ×  l0  T sheep E that bore 1.5 C3b,Bb,P sites/cell 
(19) in 0.1 ml of this buffer were added, and incubation was continued for 20 rain at 30°C. The 
residual C3b,Bb,P sites were hemolytically developed by addition of 0.3 ml of rat serum diluted 
in veronal-buffered saline containing 40 mM EDTA, and incubation for was continued 60 rain 
more at  37°C.  The percent hemolysis was measured and  the average number of hemolytic 
sites/cell was calculated. 
Assay of Complement Receptors on Peripheral Blood Cells by Formation of Rosettes with Sheep E  That 
Bore C3b, C3bi, or C3d.  C3  (20),  B  (21),  D  (19),  P  (22),  ~IH  (23),  and  C3bINA  (24)  were 
purified to homogeneity as assessed by SDS-PAGE. C3 was radiolabeled with 125I to a  20,000 
cpm/#g sp act by use of insoluble lactoperoxidase (18). Sheep EC3b that bore 8,500 ~SI-C3b/ 
E  were prepared by interaction of trypsinized E  with  125I-C3, B, and  D, as described (25). 
Sheep EC3bi were prepared by incubation of the EC3b with 5 #g C3bINA/ml and 50 #g ~ 1  H/ 
ml for 45 min at 37°C. This treatment abolished the capacity of these cells to form cell-bound 
C3b,Bb,P sites, but did not decrease their content of ceil-bound 125I (26).  Sheep EC3d were 
prepared by incubating the EC3bi with 0.1 #g tryspin/ml for 40 min at 37°C, which resulted 
in a 90% decrease in cell-bound x251 (26). 
Human E were obtained from fresh, citrated blood and were washed five times in phosphate- 
buffered saline (PBS)  that contained 20 mM NaPO4,  120 mM NaCI, pH  7.3, and the buffy 
coat and the top 10% of E were removed after each centrifugation. PMN were isolated from 
eitrated blood by dextran sedimentation of E, and centrifugation of the leukocytes on Ficoll- 
paque cushions (Pharmacia Fine Chemicals, Div. of Pharmacia Fine Chemicals) (27). Residual 
contaminating E were hypotonically lysed in 0.2%  NaCI and the PMN were washed free of 
hemoglobin. The final preparation consisted of 98% viable PMN by morphology and exclusion 
of trypan blue. A population of cells enriched for B lymphocytes was obtained from peripheral 
blood mononuclear cells by sequential removal of cells forming rosettes with neuraminidase- 
treated sheep E (28, 29) and of cells adherent to plastic Petri dishes (30). The final preparation 
was 96%  viable by exclusion of trypan blue and contained 56% cells with membrane Ig, as 
assessed by immunofluoreseenee with fluorescein-eonjugated rabbit F(ab')2 anti-human F(ab')2 
(N. L. Cappel Laboratories Inc., Cochranville, Pa.), and 2% cells capable of ingesting sheep E 
sensitized with rabbit IgG (EA). Monocytes were isolated directly from the mononuclear cells 
by adherence to glass eoverslips and were 86-91% phagocytic, as assessed by ingestion of sheep 
EA. 
1 ×  106 E, PMN, and B lymphocytes, respectively, were incubated for 30 rain at 30°C with 
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albumin/ml and 1 mg soybean trypsin inhibitor/ml (PBS-BSA-SBTI). These reaction mixtures 
also contained variable concentrations of preimmunization and anti-gp205 F(ab')2, respectively, 
ranging from none to  12.8 p~/ml. Monolayers of monocytes were overlaid with 0.2 ml of this 
buffer that contained 1 × 10  of the sheep E intermediates and the same concentrations of the 
preimmunization and anti-gp205 F(ab')2 and were incubated for 30 rain at 37°C. To assess the 
formation of rosettes in  the cell suspensions, a  drop was placed on  a  microscope slide and 
covered  with  a  coverslip;  200  human  cells were  then  examined  at  ×  900  magnification. 
Formation of rosettes by monocytes was also microscopically assessed after rinsed coverslips 
carrying the monocytes were placed over drops of PBS-BSA-SBTI on microscope slides. Binding 
of the two or more sheep E to an human E, and three or more sheep E to a PMN, B lymphocyte, 
or monocyte was considered a rosette. 
Assay of Binding of t~l-F(ab')2 Anti-gp205 to Human Peripheral Blood Cells.  1.2 ×  109 human E, 
3.3 ×  107 PMN, 5.9 ×  107 peripheral blood mononuclear cells enriched for B lymphocytes and 
that contained 52% membrane-Ig-bearing cells and 60% cells capable of forming rosettes with 
sheep EC3b, and 7 ×  10  z cells of a  preparation of T  lymphocytes that  had been isolated by 
rosette formation with neuraminidase-treated sheep E  (28, 29) were suspended at 4°C in 1 ml 
of PBS-BSA-SBTI. To  five replicate samples of 75/~1  of each cell type were added  100/~g 
preimmunization F(ab')2 in 20/~1 PBS, and  100/xg F(ab')2 anti-gp205 was added in PBS to an 
additional  five  reFlicate samples.  After  incubation  for  20  rain  at  4°C,  pairs  of samples 
containing  the  pre-  and  postimmunization  F(ab")2  received  10  /xl  of PBS  that  contained 
increasing amounts of lznI-F(ab')2 anti-gp205, ranging from 0.08 pg to 2.5 #g, and incubation 
was continued for 60 rain at 4°C while the cells were intermittently agitated. Duplicate 40 #1 
samples of each reaction mixture were layered on 300/~1 of a mixture of six volumes of dibutyl 
phthalate and four volumes of dinonyl phthalate in 400/~1 microtest tubes. After centrifugation 
at 8,000 g for 75 see in a Beckman B microcentrifuge (Beckman Instruments, Inc., Spinco Div., 
Palo Alto, Calif.), tubes were cut to yield tips containing the cell pellets and upper portions 
containing the ceil-free aqueous phases. Each was assessed for 125I to measure cell-bound and 
unbound 125I-F(ab')2, respectively. 
125T  ~  6  To assay binding of  I-F(ab')2 anti-gp205 to monocytes, 4 ×  10  mononuclear cells from the 
Ficollpaque cushions  in  0.2  ml  RPMI  1640  medium  (Grand  Island Biological Co.,  Grand 
Island, N. Y.) supplemented with  10% heat-inactivated fetal calf serum (FCS) were added to 
each of 22 round-bottomed 1- x  10-cm  glass tubes, and incubated for 30 rain at 37°C in the 
presence of 5% CO2. Nonadherent cells were removed from the tubes by the addition of 3 ml 
PBS-BSA-SBTI, light agitation of the tubes, removal of the supernates, and repetition of this 
procedure. The washed monolayers of monocytes in  10 tubes received 200 pg of preimmuni- 
zation F(ab')2 in  140 pl PBS-BSA-SBTI and an additional 10 monolayers received 200 pg of 
unlabeled F(ab')2 anti-gp205. After incubation for 20 min at 4°C,  pairs of tubes containing 
preimmunization and  anti-gp205  F(ab')z, respectively, received  10  #1  PBS-BSA-SBTI  that 
125  contained  increasing  amounts  of  I-F(ab')z anti-gp205  ranging  from  0.31  to  5  #g,  and 
incubation was continued for 60 min  at 4°C.  All tubes received  1 ml of ice-cold PBS-BSA- 
SBTI and  were centrifuged at 900 g  for  10  rain at 4°C;  the supernates were removed and 
assessed for unbound 125I-F(ab')2. The cells were washed twice by repetitive additions of 1 ml 
of this buffer, centrifugation, and aspiration of the supernates. Cell-associated ~2SI-F(ab')2 was 
measured in the material released from the washed monolayers by addition of 1 ml PBS-BSA- 
SBTI that contained 0.5%  NP-40. The number of cells in the monolayers was estimated as  1 
×  10  e by counting the nuclei released after detergent solubilization of cells in two additional 
tubes containing monolayers (31). 
Surface Radioiodination of Peripheral Blood Cells and Identification of the Membrane Proteins Reacting 
with  Anti-gp205.  Human  E,  5  ×  l0  s  cells, were  suspended  in  15  ml  of PBS  at  0°C  with 
constant stirring, and 500 pg lactoperoxidase (Sigma Chemical Co., St. Louis, Mo.), 750 pCi of 
Na[lZSI], and 0.015 #mol H202 were sequentially added (32, 33). During continued incubation 
at 0°C, addition of H202 was repeated at 3, 6, and 9 min, and addition of laetoperoxidase was 
repeated at 6 min. After 12 min, the E were sedimented by centrifugation at 4°C, washed once 
with ice-cold PBS, and washed three times with PBS-bovine serum albumin (BSA). The E were 
lysed by suspension in  15 ml of buffer that contained 5 mM NaPO4, 0.5 mM EDTA, pH 8.0, 
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were washed by resuspension in  15  ml of this buffer and recentrifugation. In four separate 
experiments, 96-98% of 1~I that was associated with the labeled intact E was recovered in the 
washed membranes. The membranes were suspended in 2 ml of PBS that contained 0.5% NP- 
40 and 5 mM diisopropyl fluorophosphate (DFP)  (Sigma Chemical Co.), held at 0°C for 60 
min, and centrifuged at 48,200 g for 40 rain. The supernates, which contained the solubilized 
membrane proteins, were removed and stored at -70°C. 
1 X  10  a PMN were iodinated with 750/xCi of l~sI by the procedure described for labeling of 
E, except that the volume and reagents utilized in the reaction were reduced fivefold. In two 
separate experiments, 92  and 94%  of the PMN  excluded trypan blue after iodination. The 
PMN were suspended by vigorous vortexing in 2 ml of ice-cold PBS that contained 0.5%  NP- 
40  and  5  mM  DFP, held at 0°C  for 60 min  and  centrifuged at  48,200 g  for 60 min.  The 
supernates that contained solubilized membrane proteins were removed and stored at -70°C. 
Mononuclear ceils, 2.5  ×  10  a, which had been depleted of cells that  formed rosettes with 
neuraminidase-treated sheep E, were iodinated with 1 mCi of l~sI by the procedure described 
for  E  with  a  twofold  reduction  in  the  reaction  volume  and  reagents.  2.5  X  108  labeled 
mononuclear cells in 5 ml of RPMI-1640 medium that contained FCS were added to each of 
five plastic Petri dishes of 100-mm diameter and were incubated for 30 min at 37°C  in the 
presence of 5% CO2.  The Petri dishes were gently agitated and the supernates that contained 
7.2 ×  10  7 nonadherent cells were removed. The monolayers were washed by twice adding and 
removing 5 ml of PBS containing 2 mg BSA/ml. The nonadherent  cells were washed three 
times with  this buffer by repeated suspension and  centrifugation.  In two experiments, the 
nonadherent cells were 91 and 93% viable by trypan blue exclusion; 2 and 4% of the cells were 
capable of ingesting sheep EA, 56 and 65% were capable of forming rosettes with sheep EC3b, 
and 52 and 63% reacted with fluorescein-conjugated rabbit F(ab')z anti-human F(ab')2. In two 
experiments, the adherent cells were 91 and 94% viable; 82 and 89% of the cells were capable 
of ingesting sheep EA. The adherent cells were removed from the Petri dishes by the addition 
of 5 ml PBS that contained 0.5% NP-40 and 5 mM DFP to one dish, swirling, and passing the 
buffer to the next dish. The released material was held at 0°C for 60 min and then centrifuged 
at 48,200 g for 40 min; the supernate was removed and stored at -70°C. Membrane proteins 
of nonadherent cells were solubilized and obtained by the procedure described for E and PMN. 
The solubilized membrane proteins from each cell type were partially purified by affinity 
chromatography on Sepharose-C3 (16). The supernates of the NP-40 extracts were diluted with 
six volumes of 10 mM NaPO4, pH 7.1, that contained 2 mg BSA/ml and 5 mM DFP, and were 
applied to 1.5-ml columns of Sepharose-C3. The columns were washed with the diluting buffer 
and were eluted by application of this buffer that contained 400 mM NaCI and 0.5%  NP-40. 
Solubilized 125I-labeled  membrane  proteins in  2  ml  of the  buffer  utilized  for elution  of 
Sepharose-C3 were immunoprecipitated by the addition of 50 #g of preimmunization IgG or 
anti-gp205 rabbit IgG, incubation for 60 min at 4°C, and addition of 100/~i of a  10% suspension 
of Staphylococcus aureus, Cowan I strain (34).  After incubation for 30 rain at 4°C,  the bacteria 
were sedimented by centrifugation at 5,000 g for 15 min and washed 3 times. Proteins bound 
to the bacteria were released by suspending the particles in 200 #1 of PBS that contained 2% 
SDS and 5% 2-mercaptoethanol at  100°C  for  1 min. The released material was subjected to 
SDS-PAGE according to the method of Laemmli (35) and ~5I was assayed in l-ram sections of 
the gels. 
Results 
Rabbit Antibody to gp205 of Human ETythrocytes Inhibits CSb-Receptor Function of Peripheral 
Blood Cells.  The  IgG  fractions  of sera  that  had  been  obtained  before  and  after 
immunization  of a  rabbit with  purified  gp205  of human  E  were  compared  for the 
capacity to  neutralize  the  inhibitory activity of gp205.  Incubation  of sheep  E  that 
bore ~ 1.5  C3b,Bb,P sites/cell with buffer alone for 20  min at  30°C  resulted in 0.93 
residual sites/cell, wheres incubation of the cells with  10 ng gp205/ml  decreased the 
number  of C3b,Bb,P sites/cell to 0.16.  Preimmunization  rabbit  IgG did not  impair 
the inhibitory activity of gp205. In contrast, postimmunization IgG neutralized gp205 24  C3b  RECEPTOR  OF  HUMAN  PERIPHERAL  BLOOD  CELLS 
in a  dose-response manner,  and complete blocking of inhibition  was achieved with 
concentrations of 2/~g IgG/ml or higher (Fig. 1), indicating that the postimmunization 
rabbit IgG had specificity for gp205. 
The capacity of anti-gp205 to impair C3b-receptor function was assessed.  Human 
E, PMN, monocytes, and B lymphocytes were incubated with sheep EC3b in buffer 
alone or buffer that contained increasing concentrations of F(ab')2 anti-gp205 and the 
percent of human cells forming rosettes was quantitated.  Anti-gp205 inhibited in a 
dose-response manner the capacity of each type of cell to bind sheep EC3b (Fig.  2), 
with 50% inhibition occurring at 0.13/~g/ml, 0.90/~g/ml,  1.20  lag/ml, and 1.25 #g/ml 
of F(ab')2 for E,  B  lymphocytes, PMN,  and  monocytes, respectively.  1 mg/ml  of 
preimmunization F(ab')z did not impair rosette formation by any of the four types of 
cells.  Thus,  rabbit  antibody that  neutralizes  the  inhibitory  activity of gp205  also 
impairs the function of C3b receptors of peripheral blood cells. 
The monospecificity of anti-gp205 for the C3b receptor was analyzed by examining 
the  effect of 20 #g  F(ab')2/ml  on  the  formation  of rosettes  by monocytes and  B 
lymphocytes with sheep EC3b, EC3bi, and EC3d. Almost all monocytes bound sheep 
EC3b, approximately one-half that  number bound EC3bi, and  none had adherent 
EC3d (Table I). The frequency of rosettes in the B lymphocyte population also was 
greater with EC3b than with EC3bi, and a small proportion bound EC3d. The single 
high concentration of F(ab')2 anti-gp205 that totally inhibited C3b receptor-depend- 
ent rosette formation by both types of cells had no effect on the function of their C3bi 
and C3d receptors. 
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Fla.  1.  Dose-response  relationship between the concentration ofpreimmunization (O) and postim- 
munization (O) rabbit-IgG with which gp205 had been preincubated, and the capacity of gp205 to 
inhibit C3b,Bb,P sites on sheep E during subsequent incubation for 20 min at 30°C. The number 
of C3b,Bb,P sites/sheep E that had been incubated with buffer instead of gp205 was 0.93. 
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FIG.  2.  Dose-response  relationship between the concentration of F(ab')2 anti-gp205 and the percent 
of human E  (A),  B lymphocytes (A),  monocytes (O),  and PMN  (0)  forming rosettes with sheep 
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TABLE  I 
Percent of Cells in Preparations of Monocytes and B Lymphoeytes that Form 
Rosettes with Sheep Eopthrocytes that Bear C3b, C3bi, or C3d in the Presence 
or Absence of F(ab ')2 anti-gp205 
Cell preparation  EC3b  EC3bi  EC3d 
% 
Monocyte  82  36  0 
Monocyte +  anti-gp205  0  38  0 
B lymphocyte  64  12  4 
B lymphocyte +  anti-gp205  0  14  4 
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To determine whether the differing doses of F(ab')2 anti-gp205 that were required 
for 50% inhibition of C3b receptor function of human E, B lymphocytes, PMN, and 
monocytes reflected variable numbers of antigenic sites on these cells, the uptake of 
125I-F(ab')2 anti-gp205 by each of the four types of cells was quantitated.  Binding of 
l~SI-F(ab')2 anti-gp205  to each cell  type in  the presence of excess unlabeled F(ab')2 
anti-gp205  was  a  linear  function  of the  input  of labeled  ligand  and  thus  was 
nonsaturable  and  taken  to be nonspecific (Fig.  3). In contrast,  the binding of t~I- 
F(ab')2 anti-gp205  in  the presence of preimmunization  F(ab')2 was concave to the 
abcissa, indicating saturable binding reactions for each of these cell types. The specific 
uptake of x25I-F(ab')2 was obtained by subtracting the amount bound nonspecifically 
from  that  bound  in  the absence of competing  unlabeled  ligand,  and  was plotted 
according to the method of Scatchard (36) to determine the total number of antigenic 
sites/cell.  This  analysis  revealed  950  sites/E,  21,000  sites/cell  of B  lymphocyte 
preparation,  57,000 sites/PMN, and 48,000  sites/monoeyte. Comparable analysis of 
T  lymphocytes  revealed  no  specific  uptake  of  lz~I-F(ab')2.  Thus,  the  nucleated 
peripheral blood cells that are known to display C3b receptor activity had comparable 
numbers of membrane sites recognized by F(ab')2 anti-gp205,  whereas E  had >10- 
fold fewer sites/cell and T lymphocytes, which are thought not to have C3b receptors, 
had no detectable antigenic sites. 
Identification of the Membrane Protein of Human E, PMN, B  Lymphocytes, and Monocytes 
that  Reacts  with  IgG  anti-gp205.  In  preliminary  experiments,  it  was  found  that 
interaction of solubilized 12hi-labeled proteins of human E membranes with IgG anti- 
gp205  and  S.  aureus Cowan  I  precipitated  0.21%  of the  labeled proteins,  whereas 
interaction of the membrane proteins with preimmunization  IgG or with buffer and 
the bacteria precipitated  0.15% of the labeled proteins.  To increase the percent  of 
specifically immunoprecipitated 12hi-protein, the solubilized membrane proteins were 
subjected to affinity chromatography on Sepharose-C3 before interaction  with anti- 
gp205.  In  two experiments,  0.40 and  0.58%  of the applied  protein-bound~ a25I was 
recovered in the eluate of the column and 8.5 and 5.0%, respectively, of the eluted 
material  was specifically immunoprecipitated.  No  labeled  proteins  in  the  effluent 
were specifically bound by IgG anti-gp205. Thus, partial purification of E membrane 
proteins by Sepharose-C3 chromatography resulted in an 80- to  140-fold increase in 
the  percent  of labeled  proteins  specifically interacting  with  IgG  anti-gp205.  The 
solubilized,  radioiodinated  membrane  proteins  from  each  of two  preparations  of 
PMN, B lymphocytes, and monocytes were also partially purified by Sepharose-C3 
chromatography,  and  similar  results  were obtained.  Only 0.1-0.7%  of the applied 26  C3b  RECEPTOR  OF  HUMAN  PERIPHERAL  BLOOD  CELLS 
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Fie.  3:  Binding of l~I-F(ab%  rabbit  anti-gp205  to  human  E  (A),  PMN  (B),  peripheral  blood 
mononuclear cells enriched for B lymphocytes (C), and monocytes (D). In the left-hand portions of 
the  panels,  specific  binding  (O)  of ~I-F(ab%  anti-gp205  was  calculated  from  binding  in  the 
presence of preimmunization rabbit F(ab')2 (0) by subtracting the binding in the presence of excess, 
unlabeled  F(ab')2 antl-gp205  (A). The  duplicate  measurements  at  each  input  of 125I-F(ab')2  are 
indicated. In the right-hand portions of the panels are Scatchard plots of the specific binding of 12nl- 
F(ab% anti-gp205 to each type of cell. Each point is the mean of the duplicate determinations. 
protein-bound 125I was recovered in the eluate of the Sepharose-C3 columns, and 4- 
10.4% of eluted proteins were specifically immunoprecipitated. 
The immunoprecipitated proteins of each type of cell were subjected to SDS-PAGE 
and the  1-mm slices of the  gels were assayed  for l~I.  A  single  peak of l~I  with an 
apparent  205,000  tool wt was seen with material  derived  from each cell. Thus,  IgG 
anti-gp205  recognized a single membrane protein of the human E, PMN, B lympho- 
cyte, and monocyte that is identical in size with gp205. 
Discussion 
Initially, gp205 was sought and characterized as a  constituent of human E  mem- 
branes that could impair activation of the human alternative complement pathway 
by these cells (16). This glycoprotein of 205,000 mol wt was purified to homogeneity 
in  its  detergent-solubilized  form  and  was  shown  to  induce  a  dose-related  loss  of 
function of C3b,Bb,P by displacement of Bb from C3b, and to promote cleavage of DOUGLAS T.  FEARON  27 
the a-polypeptide chain of C3b by C3blNA. These inhibitory activities of gp205, and 
its reversible  adsorption to Sepharose-C3  during purification suggested that gp205 
had an affinity for C3b and prompted the consideration that this membrane glyco- 
protein might have an additional function; namely, that ofserving as the C3b receptor 
of human E. 
The relation of gp205 to the C3b receptor of human E was examined by utilizing 
monospecific rabbit antibody to gp205.  2 #g/ml of the IgG fraction of serum taken 
from a rabbit that had been immunized with purified gp205 completely neutralized 
the capacity of gp20.5 to inhibit C3b,Bb,P sites on sheep  E,  whereas 2.5  times this 
concentration of  rabbit IgG taken before immunization had no effect on this inhibitory 
activity of gp205, thereby indicating that the postimmunization IgG had specificity 
for  gp205 (Fig. 1).  Evidence for  the  monospecificity of this  IgG  anti-gp205  was 
obtained by demonstrating that it immunoprecipitated a single,  l~I-labeled protein 
of 205,000 mol wt, as assessed by SDS-PAGE, on interaction with membrane proteins 
from human E that had been surface radioiodinated (Fig. 4). Thus, the capacity of 
the F(ab')2 fragment of this monospecific IgG anti-gp205 to inhibit in a dose-response 
manner the  formation of rosettes  between human E  and sheep  EC3b  established 
gp205 as the C3b receptor of  human E (Fig. 2). The additional finding that Scatchard 
analysis of the uptake of 125I-F(ab")2 anti-gp205 by human E revealed 950 antibody- 
binding sites/cell,  is similar to the estimation of 1,400 C3b receptors/human E based 
on uptake of 125I-C3 (37). 
The identity of gp205 as the C3b receptor also of human peripheral blood PMN, 
B lymphocytes, and monocytes was suggested by the capacity of F(ab')2 anti-gp205 to 
inhibit formation of rosettes by these cells with sheep EC3b (Fig. 2) without impairing 
the function of receptors  for C3bi and C3d  (38) on monocytes and B lymphocytes 
(Table I).  However, seven- to ninefold higher concentrations of the antibody were 
required to inhibit by .50% C3b receptor-dependent formation of rosettes  by these 
nucleated cells than was necessary for comparable inhibition of receptor function on 
human E. This difference was secondary to the presence of more C3b receptors on the 
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nucleated cells as Scatchard analysis of the number of specific  x25I-F(ab')2 binding 
sites revealed 21,000 sites/cell of B lymphocyte preparation, 48,000 sites/monocyte, 
and 57,000 sites/PMN (Fig. 3). Because the preparation of B lymphocytes contained 
cells that lacked membrane Ig and that did not form rosettes with sheep  EC3b, the 
number of anti-gp205-binding sites on B lymphocytes may be higher. Although the 
stoichiometry of the  interaction  of the  bivalent,  polyclonal  anti-gp205  with  its 
membrane antigen is not known, this analysis suggests that each of these nucleated 
cells may have 20- to 60-fold more C3b receptors  than human E, and accounts for the 
higher concentrations of F(ab')2  anti-gp205 required for inhibition of C3b-receptor 
function on these cells, and for the capacity of these cells to bind 10-20 sheep EC3b, 
as compared to the 2-3 EC3b that are bound by human E. The absence of specific 
binding of ~25I-F(ab')2 by  peripheral  blood  T  lymphocytes is  consistent  with  the 
inability of these cells to form rosettes with C3b-bearing particles. 
Direct  evidence for the identity of gp205 as the C3b receptor of PMN, B lympho- 
cytes, and monocytes was obtained when radioiodinated, detergent-solubilized mem- 
brane proteins of these cells were reacted with anti-gp205 and the immunoprecipitate 
was analyzed by SDS-PAGE.  IgG anti-gp205,  in the presence of protein A-bearing S. 
aureus, specifically precipitated labeled material which was derived from each of these 
cell types, and which had been enriched by affinity chromatography on Sepharose- 
C3.  In each instance, the immunoreactive material represented a  single  iodinated 
protein that exhibited an apparent 205,000 mol wt and was indistinguishable from 
the membrane protein derived from human E  (Fig. 4).  gp205,  which was  initially 
recognized  as a membrane constituent of human E that is capable of inhibiting the 
alternative complement pathway, also  serves as  the C3b  receptor  of E,  PMN,  B 
lymphoeytes, and monocytes. 
Summary 
A human erythrocyte membrane glycoprotein of 205,000 mol wt (gp205) has been 
identified  as  the  C3b  receptor  of the  erythrocyte, polymorphonuclear leukocyte 
(PMN), B lymphocyte, and monocyte. Initially, gp205 was sought and characterized 
as a constituent of the human erythrocyte membrane that can impair activation of 
the alternative complement pathway by inducing loss of function of the properdin- 
stabilized amplification C3 convertase (C3b,Bb,P)  through displacement of Bb from 
C3b  and  by  promoting cleavage-inactivation of C3b  by  C3b  inactivator.  These 
inhibitory activities  of gp205  suggested  that  this  membrane  glyeoprotein had  an 
affinity for C3b and prompted an analysis of its possible identity as the C3b receptor 
of human peripheral  blood cells. The  F(ab')2  fragment of rabbit  IgG anti-gp205 
inhibited  the  formation of rosettes  with  sheep  EC3b  of human  erythroeytes, B 
lymphocytes, monocytes and PMN in a  dose-response  manner; the 50%  inhibitory 
doses were 0.13/~g/ml, 0.90 ~g/ml, 1.25 gg/ml, and 1.20 gg/ml of F(ab')2, respectively. 
Anti-gp205 did not impair the formation of rosettes by monocytes and B lymphocytes 
with sheep  EC3bi or with EC3d. Scatchard analysis of the number of specific  125I- 
F(ab')2 anti-gp205  binding sites/cell revealed 950 sites/erythrocyte, 21,000 sites/cell 
of B lymphocyte preparation, 57,000 sites/PMN, and 48,000 sites/monocyte, indicat- 
ing that the higher concentrations of antibody that had been required for inhibition 
of rosette  formation by the nucleated cells reflected larger numbers of receptors  on 
these cells. Direct evidence for the identity of gp205 as the C3b receptor of the four DOUGLAS T.  FEARON  29 
cell types was obtained when detergent-solubilized membrane proteins of the surface- 
radioiodinated  cells were reacted  with  anti-gp205  and  the  immunoprecipitate  was 
analyzed  by polyacrylamide gel  electrophoresis  in  the  presence of sodium  dodecyl 
sulfate. In each instance, the antigenic material reacting with anti-gp205 represented 
a single protein with an apparent 205,000 mol wt. Thus, gp205 is the C3b receptor of 
human erythrocytes, PMN, B lymphocytes, and monocytes. 
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